THE ROLE OF PERSONALIZED MEDICINE IN CLINICAL TREATMENT PROTOCOLS

Abstract

Personalized medicine has emerged as a transformative approach to healthcare, shifting away from conventional "one-size-fits-all" treatments toward strategies that account for individual genetic, environmental, and lifestyle factors. This paradigm aims to enhance clinical efficacy, minimize adverse drug reactions, and optimize therapeutic outcomes across diverse patient populations.In this study, we explored the integration of genomic technologies, particularly CRISPR and next-generation sequencing (NGS), along with pharmacogenomic profiling and artificial intelligence-based decision support tools to design patient-specific treatment protocols. The methodology involved analyzing genetic variants associated with drug metabolism and disease susceptibility, followed by simulation of clinical decision-making using AI frameworks.The results demonstrate that personalized treatment strategies significantly improved patient outcomes compared to standard protocols. Specifically, pharmacogenomic-guided therapies reduced adverse drug reactions, enhanced drug efficacy, and minimized trial-and-error prescribing. Moreover, AI-assisted decision systems improved the accuracy of treatment recommendations by incorporating complex multi-omic datasets in real-time.This research underscores the critical value of integrating genomic data into routine clinical practice. Despite its promise, the widespread adoption of personalized medicine is constrained by high costs, ethical concerns regarding genetic data privacy, and disparities in access to genomic services. Addressing these barriers through policy reforms, technological innovation, and equitable healthcare frameworks will be essential to realizing the full potential of precision medicine. Ultimately, this study reaffirms that personalized medicine represents not only a scientific advancement but a necessary evolution in patient-centered care.